Cruz ARE, Roche AC, Ramírez GT

Language: Spanish
References: 10
Page:
PDF size: 193.05 Kb.

ABSTRACT

The case of a female patient in the sixth decade of life suffering from type 2 diabetes with five years of evolution, controlled by diet and a low dose oral hypoglycaemic, and presenting with a nephrotic syndrome is reported. In the clinical examination, and while assessing the results of the diagnostic procedures performed, it found that the patient did not to meet the criteria for a diabetic nephropathy. With these elements, and no presence of any disease process to justify the nephrotic syndrome, the clinical discussion was oriented towards the possibility of primary or secondary glomerular disease, versus diabetic nephropathy. It was proposed performing a renal biopsy to establish the diagnosis, which was: renal amyloidosis with a minimal mesangial pattern class II, this approach allowed the clarification of a questionable or inconclusive clinical statement.

REFERENCES

1. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, et al. A primer of amyloid nomenclature. Amyloid. 2007 Sep;14(3):179-83.

2. Picken MM. Amyloidosis-Where are we now and where are we heading? Arch Pathol Lab Med 2010;134(4):545-51.

3. Picken MM. New Insights into systemic amyloidosis: the importance of type diagnosis. Curr Opin Nephrol Hypertens. 2007 May;16(3):196-203.

5. Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, et al. A primer of amyloid nomenclature. Amyloid. 2007 Sep;14(3):179-83. 2. Picken MM. Amyloidosis-Where are we now and where are we heading? Arch Pathol Lab Med 2010;134(4):545-51. 3. Picken MM. New Insights into systemic amyloidosis: the importance of type diagnosis. Curr Opin Nephrol Hypertens. 2007 May;16(3):196-203. 4. Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int. 2008;74(2):18-22. 5. Sanchorawala V, Skinner M, Quillen K, Finn KT, Dores G, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation. Blood. 2007 Nov 15;110(10):3561-3.

6. Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, et al. Autologous stem cell transplant after heart transplant for light chain (AL) amyloid cardiomyopathy. J Heart Lung Transplant. 2008 Aug;27(8):823-9.

7. Comenzo RL, Steingart RM, Cohen AD. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007 Sep 13;357(11):1083-93.

8. Audard V, Matignon M, Weiss L, Remy P, Pardon A, Haioun C, et al. Successful longterm outcome of the first combined heart and kidney transplant in a patient with systemic AL amyloidosis. Am J Transplant. 2009 Jan;9(1):236-40.

9. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2361-71.

10. Dember LM. Modern treatment of amyloidosis: unresolved questions. J Am Soc Nephrol. 2009 Mar;20(3):469-72.